As of 2026-09-02 10:16 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal. [1]
A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. [2]
Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. [3]
MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. [4]
The plan involves immediately selling some stores to use the proceeds primarily to repay creditors. [5]
Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. [6]
This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. [7]
Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. [8]
What this stands on
A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal. · Yonhap News Agency
A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. · Yonhap News Agency
Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. · 매일경제South Korea
MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. · Yonhap News Agency
The plan involves immediately selling some stores to use the proceeds primarily to repay creditors. · Yonhap News Agency
Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. · 매일경제South Korea
This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. · 매일경제South Korea
Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. · 매일경제South Korea
The one we could place publishes from South Korea. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.
Article provenance · 8 sources · v 001worldrecordwritingfiling
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, September 2, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
The one we could place publishes from South Korea. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
The automated line wrote this as TruthFoundry News Desk using a large language model at 2026-09-02T22:46Z.
The prompts, verbatim
System instruction (the grounding rules)
The assignment: persona voice contract + this desk's standing instructions + the numbered facts
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Analytics cookies? This paper would like to use Google Analytics to see which pages are useful. It sets cookies and shares usage data with Google. Nothing loads unless you accept, and you can change your mind any time under Cookie settings in the footer. Privacy